Bristol-Myers Squibb Company / Cardioxyl Pharmaceuticals, Inc.

Acute Decompensated Heart Failure (ADHF)

1M US cases/yr · $21.0B US heart failure direct cost (AHA 2012, projected $70B by 2030)

Disease Overview

Acute decompensated heart failure is the abrupt worsening of cardiac function in patients with chronic heart failure, driving over 1 million US hospitalizations per year and ~30% one-year mortality. Despite four decades of trials, no IV inotrope has shown a survival benefit, and the standard of care remains diuretics, vasodilators, and short-acting inotropes such as dobutamine and milrinone — agents that increase heart rate and oxygen demand.

Competitive Landscape

ADHF has been a graveyard of late-stage development, with high-profile failures including Novartis's serelaxin (RELAX-AHF-2 missed in 2017) and Cytokinetics' omecamtiv mecarbil (GALACTIC-HF marginal benefit, FDA rejected 2023). When BMS acquired Cardioxyl in November 2015, the standard of care was unchanged from a decade earlier — IV diuretics (furosemide), nitrates, dobutamine and milrinone — with no agents demonstrating mortality reduction. CXL-1427 (later BMS-986231/cimlanod) was an HNO donor that improved cardiac contractility and vasodilation without raising heart rate or oxygen demand, theoretically differentiating it from existing inotropes. BMS paid $300M upfront and up to $1.775B in milestones for a Phase 2 asset described as 'high-risk, high-reward.' Phase 2a hemodynamic data were encouraging (Felker et al. 2017), but later Phase 2b STAND-UP-AHF efficacy data disappointed and BMS deprioritized the asset; rights were ultimately licensed to Windtree Therapeutics in 2018 as istaroxime/cimlanod programs continued elsewhere. The acquisition is widely cited as a cautionary example of late-stage cardiovascular bets in HF.